Boehringer Ingelheim: Psoriasis trials
The registry lists 20 Psoriasis studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 14 have results posted.
Phase 1 4Phase 2 10Phase 3 4No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment OptionsCompletedNCT05239039Phase 3Results posted
- An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment OptionsCompletedNCT05200247Phase 3Results posted
- A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With SpesolimabTerminatedNCT04493424Phase 2Results posted
- A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular PsoriasisCompletedNCT04399837Phase 2Results posted
- A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar PustulosisCompletedNCT04015518Phase 2Results posted
- A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it isTerminatedNCT03835481Phase 2Results posted
- Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular PsoriasisCompletedNCT03782792Phase 2Results posted
- This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it isCompletedNCT03635099Phase 2Results posted
- This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357CompletedNCT03279978Phase 1Results posted
- The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque PsoriasisCompletedNCT03210259Phase 3Results posted
- Initial Dosing of BI 655130 in Palmoplantar Pustulosis PatientsCompletedNCT03135548Phase 2Results posted
- Spesolimab (BI 655130) Single Dose in Generalized Pustular PsoriasisCompletedNCT02978690Phase 1Results posted
- Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02850965Phase 3Results posted
- BI 655066 Dose Ranging in Psoriasis, Active Comparator UstekinumabCompletedNCT02054481Phase 2Results posted
- Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular PsoriasisWithdrawnNCT06886009
- A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque PsoriasisCompletedNCT05728489Phase 1
- PMS of Spesolimab I.V. in GPP Patients With Acute SymptomsCompletedNCT05670821
- BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type PsoriasisCompletedNCT02209753Phase 2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in PsoriasisCompletedNCT00848055Phase 1
- Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe PsoriasisCompletedNCT00333411Phase 2